Transaction · 0001104659-26-104405

Carter Denise P.

Carter Denise P., COO, reported an open-market or private purchase at Quoin Pharmaceuticals, Ltd. involving 20490.000000 shares for an estimated $99991.20. Reported holdings after the transaction were 37709.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCOO
QNRXQuoin Pharmaceuticals, Ltd.
Trade date
Aug 31, 2026
Filing date
Sep 02, 2026
View on SEC Insider profile
Estimated value$99.9kShares × reported price
Shares traded20.4k$4.88 per share
Holdings after37.7kDirect
% of reported position traded119%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 17,219 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

QNRX price since this filing

Daily closing prices, with the filing date and available return windows
QNRX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -34.0%1w ago -19.6%1d ago -20.2%
Returns since7d +3.4%30d -30.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001104659-26-104405
ADSs
Transaction date
Aug 31, 2026
Filed Sep 02, 2026, 01:40 AM · 2d delay
Shares
20,490 sh
$4.88 per share
Estimated value
$99.9k
Computed from shares × price
Holdings after
37,709 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Buy Director Buy Direct Ownership Large Holdings Increase
Filing-only score

+50 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • director_buy+6 points

    is_director = true

    Director open-market purchase.
  • cluster_buy+14 points

    cluster-buy signal matched

    Multiple insiders bought within the configured window.
  • large_holdings_increase+8 points

    large-holdings-increase signal matched

    Reported acquired shares meet the configured percentage of post-transaction holdings.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Operating Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

  2. F2

    Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

  3. F3

    The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

  4. F4

    The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical tr…

Original filing · 0001104659-26-104405
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

QNRX